Core Points - BillionToOne, Inc. has announced the pricing of its upsized initial public offering (IPO) of 4,551,100 shares at a price of $60.00 per share, with gross proceeds expected to be approximately $273.1 million [1] - The IPO is set to begin trading on the Nasdaq Global Select Market under the ticker symbol "BLLN" on November 6, 2025, and is expected to close on November 7, 2025, subject to customary closing conditions [1] - The underwriters have a 30-day option to purchase an additional 682,665 shares at the initial public offering price [1] Company Overview - BillionToOne is a molecular diagnostics company headquartered in Menlo Park, California, focused on creating powerful and accurate tests that are accessible to all [5] - The company utilizes a patented technology called Quantitative Counting Templates™ (QCT™), which is the only multiplex technology capable of accurately counting DNA molecules at the single-molecule level [5] Underwriters - The joint book-running managers for the offering include J.P. Morgan, Piper Sandler, Jefferies, and William Blair, with Stifel, Wells Fargo Securities, and BTIG also acting as book-running managers [2]
BillionToOne Announces Pricing of Upsized Initial Public Offering